Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.51 |
| ▸ | TNKS | O95271 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4963257 | 1.00 | EPHX2 (0.51) | EPHX2TNKSPARP1PARP2TNKS2 | |
| Hydrochloric Acid SCHEMBL20357430 | 0.98 | EPHX2 (0.50) | EPHX2TNKSPARP1PARP2TNKS2 | |
| SCHEMBL18530449 | 0.86 | EPHX2 (0.47) | EPHX2TNKSPARP1PARP2TNKS2 | |
| SCHEMBL18530356 | 0.86 | EPHX2 (0.47) | EPHX2TNKSPARP1PARP2TNKS2 | |
| SCHEMBL14630693 | 0.85 | EPHX2 (0.58) | EPHX2FAAHTEAD1 | |
| SCHEMBL14630694 | 0.85 | EPHX2 (0.58) | EPHX2FAAHTEAD1 | |
| SCHEMBL20357347 | 0.80 | AR (0.45) | EPHX2TNKSPARP1PARP2FAAH | |
| SCHEMBL24011176 | 0.80 | KDM1A (0.50) | EPHX2TNKSPARP1PARP2TNKS2 | |
| SCHEMBL18615484 | 0.80 | KDM1A (0.50) | EPHX2TNKSPARP1PARP2TNKS2 | |
| SCHEMBL31540092 | 0.79 | HRH1 (0.43) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| EP-1758580-A4 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1758580-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006012226-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | HSD11B1, HSD3B1, HSD11B2 | EPHX2 1552/4885TNKS 1916/4885PARP1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.